244 related articles for article (PubMed ID: 35244715)
1. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells.
Ai Y; Liang D; Wilusz JE
Nucleic Acids Res; 2022 Jun; 50(11):e65. PubMed ID: 35244715
[TBL] [Abstract][Full Text] [Related]
2. Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13.
Burris BJD; Molina Vargas AM; Park BJ; O'Connell MR
Methods; 2022 Oct; 206():58-68. PubMed ID: 35987443
[TBL] [Abstract][Full Text] [Related]
3. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.
Liu L; Pei DS
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232699
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
O'Connell MR
J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
[TBL] [Abstract][Full Text] [Related]
5. CASowary: CRISPR-Cas13 guide RNA predictor for transcript depletion.
Krohannon A; Srivastava M; Rauch S; Srivastava R; Dickinson BC; Janga SC
BMC Genomics; 2022 Mar; 23(1):172. PubMed ID: 35236300
[TBL] [Abstract][Full Text] [Related]
6. Programmable RNA targeting with CRISPR-Cas13.
Shi P; Wu X
RNA Biol; 2024 Jan; 21(1):1-9. PubMed ID: 38764173
[TBL] [Abstract][Full Text] [Related]
7. A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila.
Huynh N; Depner N; Larson R; King-Jones K
Genome Biol; 2020 Nov; 21(1):279. PubMed ID: 33203452
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the activation of a compact CRISPR-Cas13 nuclease.
Deng X; Osikpa E; Yang J; Oladeji SJ; Smith J; Gao X; Gao Y
Nat Commun; 2023 Sep; 14(1):5845. PubMed ID: 37730702
[TBL] [Abstract][Full Text] [Related]
9. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
Tong H; Huang J; Xiao Q; He B; Dong X; Liu Y; Yang X; Han D; Wang Z; Wang X; Ying W; Zhang R; Wei Y; Xu C; Zhou Y; Li Y; Cai M; Wang Q; Xue M; Li G; Fang K; Zhang H; Yang H
Nat Biotechnol; 2023 Jan; 41(1):108-119. PubMed ID: 35953673
[TBL] [Abstract][Full Text] [Related]
10. The double life of CRISPR-Cas13.
Bot JF; van der Oost J; Geijsen N
Curr Opin Biotechnol; 2022 Dec; 78():102789. PubMed ID: 36115160
[TBL] [Abstract][Full Text] [Related]
11. Structure and engineering of the minimal type VI CRISPR-Cas13bt3.
Nakagawa R; Kannan S; Altae-Tran H; Takeda SN; Tomita A; Hirano H; Kusakizako T; Nishizawa T; Yamashita K; Zhang F; Nishimasu H; Nureki O
Mol Cell; 2022 Sep; 82(17):3178-3192.e5. PubMed ID: 36027912
[TBL] [Abstract][Full Text] [Related]
12. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.
Meeske AJ; Marraffini LA
Mol Cell; 2018 Sep; 71(5):791-801.e3. PubMed ID: 30122537
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic targeting of host RNA by Cas13 constrains its utility.
Li Z; Li Z; Cheng X; Wang S; Wang X; Ma S; Lu Z; Zhang H; Zhao W; Chen Z; Yao Y; Zhang C; Chao L; Li W; Fei T
Nat Biomed Eng; 2024 Feb; 8(2):177-192. PubMed ID: 37872368
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.
Wang B; Zhang T; Yin J; Yu Y; Xu W; Ding J; Patel DJ; Yang H
Mol Cell; 2021 Mar; 81(5):1100-1115.e5. PubMed ID: 33472057
[TBL] [Abstract][Full Text] [Related]
15. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
Perčulija V; Lin J; Zhang B; Ouyang S
Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
[TBL] [Abstract][Full Text] [Related]
16. In silico optimization of RNA-protein interactions for CRISPR-Cas13-based antimicrobials.
Park HM; Park Y; Berani U; Bang E; Vankerschaver J; Van Messem A; De Neve W; Shim H
Biol Direct; 2022 Oct; 17(1):27. PubMed ID: 36207756
[TBL] [Abstract][Full Text] [Related]
17. Potential Use of CRISPR/Cas13 Machinery in Understanding Virus-Host Interaction.
Bayoumi M; Munir M
Front Microbiol; 2021; 12():743580. PubMed ID: 34899631
[TBL] [Abstract][Full Text] [Related]
18. Collateral activity of the CRISPR/RfxCas13d system in human cells.
Shi P; Murphy MR; Aparicio AO; Kesner JS; Fang Z; Chen Z; Trehan A; Guo Y; Wu X
Commun Biol; 2023 Mar; 6(1):334. PubMed ID: 36977923
[TBL] [Abstract][Full Text] [Related]
19. Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells.
Ding Y; Tous C; Choi J; Chen J; Wong WW
Nat Commun; 2024 Feb; 15(1):1572. PubMed ID: 38383558
[TBL] [Abstract][Full Text] [Related]
20. Rapidly Characterizing CRISPR-Cas13 Nucleases Using Cell-Free Transcription-Translation Systems.
Wandera KG; Beisel CL
Methods Mol Biol; 2022; 2404():135-153. PubMed ID: 34694607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
